News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.
It targets two hormone receptors, GIP and GLP-1. Semgalutide, known as Ozempic for diabetes and Wegovy for weight loss, is also part of this broad class of drugs.
By Maggie Fick and Louise Rasmussen Sept 20 (Reuters) - Swiss medical technology company Ypsomed YPSN.S announced on Wednesday a long-term supply deal with Novo Nordisk NOVOb.CO for autoinjectors ...
It targets two hormone receptors, GIP and GLP-1. Semgalutide, known as Ozempic for diabetes and Wegovy for weight loss, is also part of this broad class of drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results